Compare · DXCM vs UTMD
DXCM vs UTMD
Side-by-side comparison of DexCom Inc. (DXCM) and Utah Medical Products Inc. (UTMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and UTMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $31.61B, about 140.7x UTMD ($224.6M).
- DXCM has been more active in the news (9 items in the past 4 weeks vs 8 for UTMD).
- DXCM has more recent analyst coverage (25 ratings vs 0 for UTMD).
- Company
- DexCom Inc.
- Utah Medical Products Inc.
- Price
- -
- -
- Market cap
- $31.61B
- $224.6M
- 1M return
- -4.56%
- -
- 1Y return
- +35.64%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 9
- 8
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Utah Medical Products Inc.
Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO umbilical vessel catheters; DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; FINESSE+ generators; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS endoscopic irrigation devices; suprapubic catheterization; LIBERTY urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN tool to manipulate the uterus in laparoscopic procedures. Additionally, the company offers DELTRAN, a disposable pressure transducer; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices through direct customer service and sales force, independent consultants, and manufacturer representatives. The company was incorporated in 1978 and is headquartered in Midvale, Utah.
Latest DXCM
- Director Ashley Euan A. gifted 2,389 shares (SEC Form 4)
- Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign
- SEC Form 10-Q filed by DexCom Inc.
- SEC Form 8-K filed by DexCom Inc.
- Dexcom Reports Third Quarter 2026 Financial Results
- EVP Chief People & Culture Off Stern Sadie sold $201,660 worth of shares (2,565 units at $78.62) as part of a pre-agreed trading plan (SEC Form 4)
- Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November
- EVP Chief Legal Compliance Off Brown Michael Jon sold $145,316 worth of shares (1,700 units at $85.48) as part of a pre-agreed trading plan (SEC Form 4)
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target
Latest UTMD
- Utah Medical Products Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Utah Medical Products, Inc. Increases Quarterly Dividend
- Chairman, CEO Cornwell Kevin L bought $66,750 worth of shares (1,000 units at $66.75) (SEC Form 4)
- Amendment: SEC Form SC TO-I/A filed by Utah Medical Products Inc.
- Utah Medical Products, Inc. Reports Corrected Results of Tender Offer
- Utah Medical Products, Inc. Reports Results of Tender Offer
- SEC Form 8-K filed by Utah Medical Products Inc.
- UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2026
- Amendment: SEC Form SC TO-I/A filed by Utah Medical Products Inc.
- Utah Medical Products, Inc. Extends Tender Offer